Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors

J. Desai, M. Voskoboynik, B. Markman, Jeannie Hou, Dewan Zang, Tarek Meniawy

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Fingerprint

Dive into the research topics of 'Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences